Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BX002-A · 1 trial · 1 indication
Evaluated by reviewing adverse events
| Arm | Type | Description |
|---|---|---|
| BX002-A | EXPERIMENTAL | BX002-A: 1 mL liquid for multiple dose oral administration |
| Placebo | PLACEBO_COMPARATOR | Placebo: 1 mL liquid for multiple dose oral administration |
| Name | Type | Description |
|---|---|---|
| BX002-A | BIOLOGICAL | bacteriophage cocktail |
| Placebo | OTHER | Placebo |
Inclusion Criteria: 1. Healthy adults 18-65 years old 2. Able to understand study procedures and sign informed consent Exclusion Criteria: 1. Evidence or history of clinically significant underlying conditions 2. Women who are pregnant or nursing, or plan to become pregnant during study, or women...
BX002-A is an investigational monoclonal antibody being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety, tolerability, and fecal pharmacokinetics in healthy adults. BX002-A is not approved for any indication and remains under investigation.
BX002-A is being developed by BiomX Inc., a biopharmaceutical company. BiomX Inc. is publicly traded under the ticker symbol PHGE. The company is conducting clinical research on BX002-A as an investigational monoclonal antibody.
BX002-A is in Phase 1 clinical development. A Phase 1 trial has been completed, which studied the safety, tolerability, and fecal pharmacokinetics of BX002-A in healthy adults. BX002-A is investigational and has not been approved by regulatory authorities.
BX002-A has one completed clinical trial, identified as NCT04737876. This Phase 1 study evaluated the safety, tolerability, and fecal pharmacokinetics of BX002-A in healthy adults in the United States. The trial enrolled 18 participants and was placebo-controlled.
No, BX002-A is not FDA approved. It is an investigational monoclonal antibody currently in Phase 1 clinical development. A Phase 1 trial in healthy volunteers has been completed, but BX002-A has not received approval for any medical use.